Anzeige
Mehr »
Login
Mittwoch, 06.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
300% Aktienanstieg war nur der Vorgeschmack – Warum diese Kupferstory noch besser wird!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
651 Leser
Artikel bewerten:
(2)

Starwood Capital Group: Starwood and CELLS sell 23,000 sqm of office space in Hamburg

HAMBURG, Germany, Dec. 21, 2021 /PRNewswire/ -- Funds managed and controlled by Starwood Capital Group, through a JV with operating partner CELLS Group, have sold two Hamburg office properties, Sachsenkamp and Kieler Park, with a total rental area of 22,900 sqm on December 1, 2021. The parties initially acquired the portfolio in December 2017. Both Sachsenkamp and Kieler Park were sold to European institutional investors for undisclosed purchase prices.

Federico Bianchi, Managing Director at Starwood Capital commented: "The high degree of investor interest in these properties confirms that well located and managed office assets continue to be in demand. Over the past four years, our value-add strategy for both properties was focused on securing high-calibre tenants of superior covenant strength, including public sector entities and blue chip national and international corporates."

Thomas Ostermann, Managing Director at the CELLS Group added: "Our hands-on asset management approach allowed us to successfully re-let under-rented space at market levels, achieving full occupancy on both assets within just two years and securing a considerable increase in net operating income. Both properties have proven very resilient throughout the pandemic and did not suffer any rent arrears."

Sachsenkamp is a 6,700 sqm, four-storey office building, developed in 1991 and part-renovated in 2013. The property is fully let, with the main tenant being an international pharmaceutical company with a top credit rating, occupying c.40% of total leasable area. The Hammerbrook S-Bahn station is only a short walk away from the property.

Kieler Park is a 16,200 sqm office complex consisting of four buildings, all developed in 1994. The property is fully let to a diversified tenant roster, the largest occupier being a publicly listed German manufacturing company. The complex is located in Hamburg's Eimsbüttel submarket within a ten-minute walk from the lively Osterstraße and close to the "Diebsteich" train station, which will undergo a major expansion over the coming years.

Starwood and CELLS Group received legal advice from GSK Stockmann and technical advice from CBRE. The buyers received legal advice from P + P Pöllath + Partners, technical advice from WBRE and environmental advice from Arcadis. CBRE acted as intermediary.

About Starwood

Starwood Capital Group is a private investment firm with a core focus on global real estate, energy infrastructure and oil & gas. The Firm and its affiliates maintain 16 offices in seven countries around the world, and currently have approximately 4,000 employees. Since its inception in 1991, Starwood Capital Group has raised over $65 billion of capital, and currently has over $105 billion of assets under management. Through a series of comingled opportunity funds and Starwood Real Estate Income Trust, Inc. (SREIT), a non-listed REIT, the Firm has invested in virtually every category of real estate on a global basis, opportunistically shifting asset classes, geographies and positions in the capital stack as it perceives risk/reward dynamics to be evolving. Starwood Capital also manages Starwood Property Trust (NYSE: STWD), the largest commercial mortgage real estate investment trust in the United States, which has successfully deployed over $76 billion of capital since inception and manages a portfolio of over $21 billion across debt and equity investments. Over the past 30 years, Starwood Capital Group and its affiliates have successfully executed an investment strategy that involves building enterprises in both the private and public markets. Additional information can be found at starwoodcapital.com.

About the CELLS Group

The CELLS Group has been developing, realizing and managing residential and commercial properties in Germany for more than 25 years.

An experienced team of more than 100 employees in Berlin, Munich, Frankfurt am Main, Hamburg, Düsseldorf and Luxembourg ensures consistently high quality and sustainability of the real estate portfolio. The operational strength and reliability make the CELLS Group a recognized and renowned business partner for tenants, service providers, private investors, family offices and institutional investors.

Since it was founded, the CELLS Group has bought and implemented projects with a total volume of more than 3.6 billion euros.

Contact:
Tom Johnson
TBJ@ABMAC.COM
(917) 747-6990

Logo - https://mma.prnewswire.com/media/1044107/Starwood_Capital_Logo.jpg

© 2021 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.